Articles > IMMP Stock Alert: Lawsuits Filed Against Immutep Limited
- Class action lawsuits have been filed against Immutep Limited for securities fraud violations
- Investors who purchased or acquired Immutep securities between March 24, 2025, and March 12, 2026, are affected
- Various law firms, including Robbins LLP, Faruqi & Faruqi, LLP, Rosen Law Firm, and Gainey McKenna & Egleston, are involved in representing investors
- Immutep is an Australian biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases
- Investors are encouraged to contact the respective law firms to discuss their legal rights
Robbins LLP, a shareholder rights law firm, has issued a reminder to stockholders regarding the class action lawsuit filed against Immutep Limited. The lawsuit represents investors who purchased or acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025, and March 12, 2026. Immutep, an Australian biotechnology company, is dedicated to developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases.
In a separate advisory, Faruqi & Faruqi, LLP has set a deadline alert for investors involved in the Immutep class action lawsuit. The firm encourages investors who suffered losses during the specified period to reach out directly to partner James (Josh) Wilson to discuss their options. Wilson can be contacted at 877-247-4292 or 212-983-9330 (Ext.
Rosen, a recognized investor counsel, has also chimed in by advising Immutep Ltd. investors to secure legal counsel before an upcoming deadline in the securities class action. The law firm announced a class action lawsuit on behalf of individuals who purchased ADRs of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025, and March 12, 2026. Similarly, Gainey McKenna & Egleston disclosed that a securities class action lawsuit has been initiated in the United States District Court for the Southern District of New York for those who bought or acquired Immutep American Depositary Receipts during the Class Period.
Rosen Law Firm has urged Immutep Ltd. stockholders to get in touch with the firm for further information about their rights as part of the ongoing class action lawsuit. The firm described Immutep as an Australian biotechnology company that focuses on developing immunotherapies related to Lymphocyte Activation Gene-3 (LAG-3) for cancer and autoimmune diseases. Investors seeking more details can submit a form or email attorney Philli.
Bronstein, Gewirtz & Grossman LLC also released a statement urging investors in Immutep Limited to take action following a class action lawsuit alleging investor harm due to securities fraud violations. The new lawsuit seeks recovery for investors and has set a lead plaintiff deadline of July 6, 2026. With multiple firms involved in representing investors affected by the Immutep Limited securities fraud allegations, individuals are urged to reach out to discuss their legal rights and potential options for recourse.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
IMMP Stock Alert: Lawsuits Filed Against Immutep Limited
By KlickAnalytics Data Insights | May 6, 2026 08:06PM ET
Key Points
- Class action lawsuits have been filed against Immutep Limited for securities fraud violations
- Investors who purchased or acquired Immutep securities between March 24, 2025, and March 12, 2026, are affected
- Various law firms, including Robbins LLP, Faruqi & Faruqi, LLP, Rosen Law Firm, and Gainey McKenna & Egleston, are involved in representing investors
- Immutep is an Australian biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases
- Investors are encouraged to contact the respective law firms to discuss their legal rights
Robbins LLP, a shareholder rights law firm, has issued a reminder to stockholders regarding the class action lawsuit filed against Immutep Limited. The lawsuit represents investors who purchased or acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025, and March 12, 2026. Immutep, an Australian biotechnology company, is dedicated to developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases.
In a separate advisory, Faruqi & Faruqi, LLP has set a deadline alert for investors involved in the Immutep class action lawsuit. The firm encourages investors who suffered losses during the specified period to reach out directly to partner James (Josh) Wilson to discuss their options. Wilson can be contacted at 877-247-4292 or 212-983-9330 (Ext.
Rosen, a recognized investor counsel, has also chimed in by advising Immutep Ltd. investors to secure legal counsel before an upcoming deadline in the securities class action. The law firm announced a class action lawsuit on behalf of individuals who purchased ADRs of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025, and March 12, 2026. Similarly, Gainey McKenna & Egleston disclosed that a securities class action lawsuit has been initiated in the United States District Court for the Southern District of New York for those who bought or acquired Immutep American Depositary Receipts during the Class Period.
Rosen Law Firm has urged Immutep Ltd. stockholders to get in touch with the firm for further information about their rights as part of the ongoing class action lawsuit. The firm described Immutep as an Australian biotechnology company that focuses on developing immunotherapies related to Lymphocyte Activation Gene-3 (LAG-3) for cancer and autoimmune diseases. Investors seeking more details can submit a form or email attorney Philli.
Bronstein, Gewirtz & Grossman LLC also released a statement urging investors in Immutep Limited to take action following a class action lawsuit alleging investor harm due to securities fraud violations. The new lawsuit seeks recovery for investors and has set a lead plaintiff deadline of July 6, 2026. With multiple firms involved in representing investors affected by the Immutep Limited securities fraud allegations, individuals are urged to reach out to discuss their legal rights and potential options for recourse.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.